Adventris Pharmaceuticals
Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths. If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com
Y Combinator
yc-company-directory #5186Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths. If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com
sourceAdventris Pharmaceuticals is classified as Enterprise SaaS from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Adventris Pharmaceuticals
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Floatpays Inc
match 41Floatpays is an on-demand wage access platform that helps employees access, spend, save and manage their money. The problem we are solving is that more than 75% of the 12 million employed South African’s run out of money before the end of the month, 52% of those end up borrowing money to survive. Informal lending is the only option for most borrowers, with interest rates anywhere between 30-50%. The story is the same in most African countries where payday/micro-lending has become the norm amongs
shared product terms: problem, most, run, interest; shared affiliation: Y Combinator
Sava
match 33If you are a trusts & estates attorney, RIA, fintech, or family office interested in Sava, reach us at founders@savahq.com
shared product terms: interest, reach, us, com; shared affiliation: Y Combinator
Magicflow 𐂂
match 33Prompt engineers, visual artists and AI data scientists are using Magicflow to run experiments at scale and perfect their pipelines Our product is ready to use: https://console.magicflow.ai try it out! we have some preloaded examples you can try. 🤟 Talk to us about anything! We love meeting new people https://calendly.com/magicflowai/
shared product terms: run, out, us, com; shared affiliation: Y Combinator
Kernal Biologics
match 33Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boastin
shared product terms: cancer, target, off, treat; shared affiliation: Y Combinator
Humane Genomics
match 33Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading e
shared product terms: cancer, target, off, approach; shared affiliation: Y Combinator
Numen
match 17Engineering a future without cancer deaths.
shared product terms: cancer, death; shared affiliation: Y Combinator